FDA Panel To Discuss Genentech's Avastin Use In Metastatic Breast Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
Oncologic Drugs panel considers whether progression-free survival can support approval for Avastin absent an overall survival benefit.
You may also be interested in...
Genentech Watchers Weigh Deeper Meaning Of Avastin’s Approval
FDA’s breast-cancer decision not a universal surprise, and there’s still risk in RIBBON-1.
Genentech Watchers Weigh Deeper Meaning Of Avastin’s Approval
FDA’s breast-cancer decision not a universal surprise, and there’s still risk in RIBBON-1.
Genentech To Resubmit Avastin sBLA In Mid-2007
FDA is seeking substantially more information than expected from an NCI-sponsored trial for first-line treatment of metastatic breast cancer, the company says.